Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

IRVING, Texas, Feb. 9, 2026 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.

Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.

Conference Call Details:

Date: Thursday, February 26, 2026
Time: 3:30 p.m. CT (4:30 p.m. ET)
Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4

A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

Investor Relations:
IR@CarisLS.com
917.689.3511

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-302681818.html

SOURCE Caris Life Sciences

Staff

Recent Posts

Streamline Healthcare Solutions Appoints Danny Gladden, MBA, MSW, LCSW, as Chief Clinical Officer

OAK BROOK, Ill.--(BUSINESS WIRE)--Streamline Healthcare Solutions announced the appointment of Danny Gladden, MBA, MSW, LCSW,…

23 minutes ago

Lunai Bioworks, Inc. Issues Letter to Shareholders

SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders,We have completed our AI platform in…

26 minutes ago

Medical Simulation Market worth $7.23 billion by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., Feb. 9, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Medical Simulation Market is projected…

26 minutes ago

Stryker introduces Mako Handheld Robotics with the limited market release of Mako RPS

PORTAGE, Mich., Feb. 9, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies,…

26 minutes ago

CiteAb Launches New Explore Platform for Streamlined Research Antibody & Reagent Selection

Leading life science database launches new scientific image search tool and improved reagent search engine…

26 minutes ago

Tiger Group Offers New & Late-Model GMP Biopharma Manufacturing and QC Laboratory Equipment and Inventory in Online Auction

Facility-closure sale of equipment from SoCal-based GenVivo opens on Feb. 11.PASADENA, Calif., Feb. 9, 2026…

26 minutes ago